Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC‐HF: Baseline Characteristics and Comparison with Contemporary Clinical Trials

European Journal of Heart Failure
Teerlink JR, Diaz R, Felker GM, McMurray JJ, Metra M, Solomon SD, Adams KF, Anand I, Arias‐Mendoza A, Biering‐Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo‐Leiro, MG, Dahlström U, Diaz R, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura Si, O’Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE
September 27, 2020

Clinical Implications of MiToS in ALS Patients Using FORTITUDE-ALS Data for 12 Weeks Follow Up

Poster, American Academy of Neurology 2020
Virtual Online
May 2020

CV Outcomes Trial for Omecamtiv Mecarbil Enrolls 8,256 Patients With HFrEF

Poster, American College of Cardiology & World Congress of Cardiology 2020 (ACC.20/WCC)
Virtual Online
March 28, 2020

The novel myotrope, AMG 594, is a small-molecule cardiac troponin activator that increases cardiac contractility in vitro and in vivo

Poster, Keystone Symposium: Charting a New Course for Heart Failure: From Discovery to Data
Keystone, Colorado
March 3, 2020

Characterization of the Cardiac Myosin Inhibitor CK-3773274: a Potential Therapeutic Approach for Hypertrophic Cardiomyopathy

Poster, Biophysical Society 64th Annual Meeting
San Diego, California
February 19, 2020